IL2 and neoplasm: Furthermore, L19-IL-2 monotherapy induced tumor growth delay of 8 days in a Ramos lymphoma xenograft model, whereas combination with Rituximab (anti-CD20 mAb) therapy resulted in completely tumor eradication [77].